%0 Journal Article
%T Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib
%A Austin Wise
%A Fereshteh Zare
%A Jackson Reynolds
%A Jeff Owsley
%A Matthew K. Stein
%A Mike G. Martin
%A Saradasri Karri
%J Archive of "World Journal of Oncology".
%D 2018
%R 10.14740/wjon1099w
%X While the recent development of novel therapeutics in oncology, such as small molecule kinase inhibitors (SMKIs), has enabled our ability to target disease-specific molecular pathways, the prolonged impact of these agents on the immune system and infectious risk remains to be seen. We present a 68-year-old male with refractory chronic lymphocytic leukemia (CLL) on ibrutinib monotherapy for 3 years who developed extensive cutaneous mucormycosis following a severe bullous pemphigoid (BP) flare. He received amphotericin B for 4 weeks and was continued on posaconazole with resolution of his mucormycosis infection. Consistent with a growing evidence of literature identifying opportunistic fungal infections in patients on ibrutinib therapy, providers should be cognizant of medical comorbidities that may predispose to such infections and explore methods of prevention before starting ibrutinib and other SMKIs
%K Ibrutinib
%K CLL
%K Mucormycosis
%K Small molecular kinase inhibitors
%K Fungal infection
%K Bullous pemphigoid
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942210/